Humanized cereblon mice reveal two distinct pathways of immunomodulatory drugs

Gemechu, Y, Millrine, David ORCID: https://orcid.org/0000-0002-8041-0151, Hashimoto, S, Prakesh, J, Sanchenkova, K, Metwally, H, Gyanu, P, Kang, S and Kishimoto, T 2018. Humanized cereblon mice reveal two distinct pathways of immunomodulatory drugs. Proceedings of the National Academy of Sciences 115 (46) , pp. 11802-11807. 10.1073/pnas.1814446115

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (962kB) | Preview

Abstract

Immunomodulatory drugs (IMiDs), including thalidomide derivatives such as lenalidomide and pomalidomide, offer therapeutic benefit in several hematopoietic malignancies and autoimmune/inflammatory diseases. However, it is difficult to study the IMiD mechanism of action in murine disease models because murine cereblon (CRBN), the substrate receptor for IMiD action, is resistant to some of IMiDs therapeutic effects. To overcome this difficulty, we generated humanized cereblon (CRBNI391V) mice thereby providing an animal model to unravel complex mechanisms of action in a murine physiological setup. In our current study, we investigated the degradative effect toward IKZF1 and CK-1α, a target substrate of IMiDs. Unlike WT mice which were resistant to lenalidomide and pomalidomide, T lymphocytes from CRBNI391V mice responded with a higher degree of IKZF1 and CK-1α protein degradation. Furthermore, IMiDs resulted in an increase in IL-2 among CRBNI391V mice but not in the WT group. We have also tested a thalidomide derivative, FPFT-2216, which showed an inhibitory effect toward IKZF1 protein level. As opposed to pomalidomide, FPFT-2216 and lenalidomide degrades CK-1α. Additionally, we assessed the potential therapeutic effects of IMiDs in dextran sodium sulfate (DSS)-induced colitis. In both WT and humanized mice, lenalidomide showed a significant therapeutic effect in the DSS model of colitis, while the effect of pomalidomide was less pronounced. Thus, while IMiDs’ degradative effect on IKZF1 and CK-1α, and up-regulation of IL-2, is dependent on CRBN, the therapeutic benefit of IMiDs in a mouse model of inflammatory bowel disease occurs through a CRBN–IMiD binding region independent pathway.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	National Academy of Sciences
ISSN:	0027-8424
Date of First Compliant Deposit:	29 October 2018
Date of Acceptance:	5 October 2018
Last Modified:	05 May 2023 23:40
URI:	https://orca.cardiff.ac.uk/id/eprint/116296

Citation Data

Cited 38 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item